Supplementary Figure S5 from Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

MvDN30 causes MET shedding under the experimental conditions employed in this study</p

Supplementary Materials and Methods from Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

Description of antibodies, growth factors and chemicals, immunofluorescence endocytosis assay, HGF labeling, in vivo experiment of Supplementary Figure S6</p

Supplementary Figure S2 from Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

JNJ-605 does not inhibit EGFR endocytosis</p

Supplementary Figure Legends from Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

Legends to Supplementary Figures S1-S6</p

Supplementary Figure S3 from Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

Interfering with receptor dimerization by mean of decoy MET severely affects receptor endocytosis</p

Supplementary Table 1 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of <i>HER2</i>-Amplified Gastrointestinal Carcinomas

Quantitations of phosphoproteins in cell lines and tumorgrafts treated with HER2/EGFR small-molecule inhibitors and antibodies.</p

Supplementary Figure S1 from Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody

JNJ-605 blocks MET endocytosis triggered by HGF or DO24. MvDN30 does not induce MET internalization</p

Supplementary Figure S3 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of <i>HER2</i>-Amplified Gastrointestinal Carcinomas

Signaling consequences of treatment with trastuzumab, lapatinib and their combination in HER2-positive colorectal and gastric cancer cells: Duplicate bots for HER receptors.</p

Supplementary Figure S5 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of <i>HER2</i>-Amplified Gastrointestinal Carcinomas

Signaling consequences of afatinib monotherapy and comparison with lapatinib: Duplicate blots for HER receptors.</p

Supplementary Figure S2 from Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of <i>HER2</i>-Amplified Gastrointestinal Carcinomas

Generation and biological characterization of HER2-overexpressing DiFi and HDC-142 cells.</p